Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Convertible Debt (2020 - 2025)

Tandem Diabetes Care's Convertible Debt history spans 6 years, with the latest figure at $310.0 million for Q4 2025.

  • For Q4 2025, Convertible Debt rose 0.57% year-over-year to $310.0 million; the TTM value through Dec 2025 reached $310.0 million, up 0.57%, while the annual FY2025 figure was $310.0 million, 0.57% up from the prior year.
  • Convertible Debt reached $310.0 million in Q4 2025 per TNDM's latest filing, roughly flat from $309.6 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $347.5 million in Q1 2024 to a low of $280.2 million in Q1 2021.
  • Average Convertible Debt over 5 years is $295.0 million, with a median of $284.4 million recorded in 2023.
  • Peak YoY movement for Convertible Debt: soared 43.64% in 2021, then decreased 11.16% in 2025.
  • A 5-year view of Convertible Debt shows it stood at $281.5 million in 2021, then increased by 0.63% to $283.2 million in 2022, then grew by 0.64% to $285.0 million in 2023, then increased by 8.15% to $308.3 million in 2024, then increased by 0.57% to $310.0 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Convertible Debt are $310.0 million (Q4 2025), $309.6 million (Q3 2025), and $309.1 million (Q2 2025).